Review article · 2015 · Open access

Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012)

Dipika Bansal, Anil Bhagat, Fabrizio Schifano, Kapil Gudala

Journal of Epidemiology and Global Health, 5(4), 385 · Published 1 December 2015 · DOI 10.1016/j.jegh.2015.04.006

Open PDFView at the publisherCite this paper

In brief

“Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012)” is a 2015 review article by Dipika Bansal and 3 co-authors, published in Journal of Epidemiology and Global Health. OpenAlex counts 37 citations as of 22 November 2026, which puts it in the top 8% of works published in 2015 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Journal of Epidemiology and Global Health.

Citations
37
Most cited in
2021 (7)
Field-weighted impact
0.48
References
32
Authors
4

Abstract

The present study aimed at systematically reviewing the role and extent of patient-reported outcomes (PROs) usage within the package of scientific evidence considered for marketing authorization (MA). All regulatory information published by the European Medicines Agency (EMA) for products authorized between January 2008 and December 2012 and appearing in the European Public Assessment Report (EPAR) database was examined for efficacy endpoints. The endpoints here considered included: PROs, clinician reported outcomes (CROs), and laboratory reported outcomes (LROs). LROs were the most frequently reported endpoints. Out of the 180 products here selected, 99 (55%), 67 (37%), and 30 (17%), respectively, used LROs, CROs and PROs as primary endpoints (PEs). PROs as any endpoints were used in 82 (46%) products. Out of these, PROs were documented as PE in 30 (37%), with 27 (33%) products having used PROs both as primary and non-PEs. PRO usage was most frequently identified with nervous system and antineoplastic agents. During the study period, the use of all the three types of endpoints appeared to be static. Both the regulatory bodies and the industry should ensure complete and clear reporting of all endpoints used, including PROs, to improve transparency.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bansal, D., Bhagat, A., Schifano, F., & Gudala, K. (2015). Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012). Journal of Epidemiology and Global Health, 5(4), 385. https://doi.org/10.1016/j.jegh.2015.04.006

MLA 9

Bansal, Dipika, et al. “Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012).” Journal of Epidemiology and Global Health, vol. 5, no. 4, 2015, p. 385. https://doi.org/10.1016/j.jegh.2015.04.006.

Chicago

Bansal, Dipika, Anil Bhagat, Fabrizio Schifano, and Kapil Gudala. 2015. “Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012).” Journal of Epidemiology and Global Health 5 (4): 385. https://doi.org/10.1016/j.jegh.2015.04.006.

Harvard

Bansal, D. et al. (2015) ‘Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012)’, Journal of Epidemiology and Global Health, 5(4), p. 385. doi:10.1016/j.jegh.2015.04.006.

IEEE

D. Bansal, A. Bhagat, F. Schifano, and K. Gudala, “Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012),” Journal of Epidemiology and Global Health, vol. 5, no. 4, p. 385, 2015, doi: 10.1016/j.jegh.2015.04.006.

BibTeX

@article{bansal2015role,
  title     = {{Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012)}},
  author    = {Bansal, Dipika and Bhagat, Anil and Schifano, Fabrizio and Gudala, Kapil},
  journal   = {Journal of Epidemiology and Global Health},
  year      = {2015},
  volume    = {5},
  number    = {4},
  pages     = {385},
  doi       = {10.1016/j.jegh.2015.04.006},
  url       = {https://doi.org/10.1016/j.jegh.2015.04.006}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201733
201833
201944
202044
202177
202233
202322
202422
202544
202655

Its field-weighted citation impact is 0.48: it has been cited 0.48 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • drug approval
  • European Medicines Agency
  • European Public Assessment Reports
  • efficacy endpoints
  • primary endpoint
  • clinician-reported outcomes
  • regulatory transparency

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Bansal, D., Bhagat, A., Schifano, F., & Gudala, K. (2015). Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012). Journal of Epidemiology and Global Health, 5(4), 385. https://doi.org/10.1016/j.jegh.2015.04.006

How many times has this paper been cited?

37 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Epidemiology and Global Health: sign in and open the PDF from this page.

Who wrote this paper?

Dipika Bansal, Anil Bhagat, Fabrizio Schifano, Kapil Gudala.

What is the DOI of this paper?

10.1016/j.jegh.2015.04.006, permanently at https://doi.org/10.1016/j.jegh.2015.04.006. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.